期刊文献+

晚期糖基化终产物诱导ECV304细胞株氧化增强的可能机制 被引量:1

Mechanism of Advanced Glycation End Products Induced Oxidative Effects in Cultured ECV304 Cells
下载PDF
导出
摘要 目的探讨晚期糖基化终产物诱导细胞株ECV304氧化增强的机制。方法取ECV304细胞培养,与不同浓度的晚期糖基化终产物-人血清白蛋白共孵育,或分别经NADPH氧化酶抑制剂Apocynin或蛋白激酶C抑制剂GF109203或酪氨酸蛋白激酶抑制剂Genistein预孵育0.5 h后,再与晚期糖基化终产物—人血清白蛋白共孵育,1h后收集细胞,用细胞色素C法检测O2-.,ThioGlo-1试剂检测还原型谷胱甘肽。结果12.5 mg/L、50 mg/L和200mg/L晚期糖基化终产物—人血清白蛋白可导致ECV304细胞内O2-.从1.37±0.67 nmol/(107.h)增加到3.44±0.40、10.67±0.67和10.93±0.67 nmol/(107.h),使还原型谷胱甘肽从9.54±0.41 nmol/106降低到9.02±0.21、8.41±0.34和8.02±0.18 nmol/106,两者均呈剂量依赖性。Apocynin、GF109203及Genistein均可抑制O2-.的增加及还原型谷胱甘肽的降低。结论晚期糖基化终产物-人血清白蛋白可通过蛋白激酶C和酪氨酸蛋白激酶途径激活NADPH氧化酶,引起ECV304细胞内O2-.产生及还原型谷胱甘肽降低,导致细胞内氧化增强。 Aim To elucidate the mechanism of advanced glycation end products (AGE) inducing oxidative effects in cultured ECV304 cells. Methods ECV304 cells were cultured in vitro with AGE-human serum albumin( HSA), or pretreated with Apocynin or GF109203 or Genistein for 0.5 h, then cultured with AGE-HSA. After 1 h, the level of O^2-· was measuerd with cytochrome C, the level of reduced glutathione was measured with ThioGlo- 1. Results O^2- · increased from 1.37 ± 0. 67 nmol/( 10^7. h) to 3.44 v 0.40, 10.67 ± 0.67 and 10.93 ±0.67 nmol/( 10^7. h), and reduced glutathione decreased from 9.54 ± 0.41 nmol/10^6 to 9.02 ± 0.21, 8.41 ± 0.34, mad 8.02± 0.18 nmol/10^6 after 12.5 mg/L, 50 mg/L, 200 mg/L AGE-HSA stimdating; Apocyrtin, GF109203 and Gertistein could inhibit these effects. Conchtsion AGE-HSA could activate NADPH oxidatiate enzyme via protein kinase (PKC) and tyrosine protein kinase (TPK)to induce O^2- · increasing and reduced glutathione decreasing and enhance inttracellular oxidative effects.
出处 《中国动脉硬化杂志》 CAS CSCD 2008年第8期633-635,共3页 Chinese Journal of Arteriosclerosis
关键词 病理学与病理生理学 晚期糖基化终产物 细胞株ECV304 活性氧 谷胱甘肽 Glycation End Products ECV304 Reactive Oxygen Species Glutathione
  • 相关文献

参考文献10

  • 1张桂林,刘尚喜,邓鹤秋,张训.晚期糖基化终产物激活内皮细胞核因子κB[J].中国动脉硬化杂志,2005,13(3):329-331. 被引量:15
  • 2Basta G,Lazzerini G,Massaro M,et al.Advanced glycation end products activate endothelium through signal-transduction receptor RAGE:a mechanism for amplifiation of inflammatory responses[J].Circulation,2002, 105 (7) : 816- 822.
  • 3Schmidt AM,Hori O,Brett J,et al.Cellular receptors for advanced glycation end products,Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions[J].Arterioscler Thromb, 1994, 14 (10): 1 521-528.
  • 4Wong RK,Pettit Al,Davies JE,et al.Augmentation of the neutrophil respiratory burst through the action of advanced glycation end products:a potential contributor to vascular oxidant stress[J].Diabetes,2002, 51 (9) : 2 846-853.
  • 5Bierhaus A,Illmer T,Kasper M,et al.Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE[J].Circulation,1997, 96 (7): 2262-271.
  • 6胡榕,吴可贵.核因子κB在心血管疾病中的作用的研究现状[J].中国动脉硬化杂志,2004,12(5):604-606. 被引量:17
  • 7hagen TM,Vinarsky V,Wehr CM,et al.(R)-alpha-lipoic acid reverses the age-asssociated increase in susceptibility of hepatocytes to tert-butylhydroperoxide both in vitro and in vivo[J].Antioxid Redox Signal, 2000, 2 (3) : 473-483.
  • 8Vignais PV.The superoxide-generating NADPH oxidase:structural aspects and activation mechanism[J].Cell Mol Life Sci, 2002, 59 (9) : 1 428-459.
  • 9Biberstine-Kinkade KJ,Yu L,et al.Mutagenesis of p22(phox)histidine 94.A histidine in this position is not required for flavocytochrome b558 function[J].J Biol Chem, 2002, 277 (33) : 30 368-374.
  • 10Yokoyama M,Inoue N,Kawashima S.Role of the vascular NADH/NADPH oxidase system in atherosclerosis[J].Ann NY Acad Sci,2000, 902: 241- 248.

二级参考文献38

  • 1Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, et al.Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis, 1998, 141(1): 61-75.
  • 2Cipollone F, Iezzi A, Fszia M, Zucchelli M, Pini B, Cuccurullo C, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation, 2003, 108(9): 1070-077.
  • 3Bierhaus A, Illmer T, Kssper M, Luther T, Quehenberger P, Tritschler H, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cell is dependent on RAGE. Circulation, 1997, 96(7):2262-271.
  • 4Todd B, Galina S, Peter L. The nuclear factor κB signaling pathway participates in dysregultion of vascular smooth muscle cell in vitro and in human atherosclerosis. J Bio Chem, 1997, 272(25): 15817-824.
  • 5Zieman S, Kass D. Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease. Congest Heart Fail,2004, 10(3): 144-151.
  • 6Bssta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al.Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation, 2002, 105(7): 816-822.
  • 7Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophy, Acta, 2000,1498(2-3): 99-111.
  • 8Kang JL, Pack IS, Hong SM, Lee HS, Castranova V. Silica induces nuclear factor-kappa B activation through tyrosine phosphorylation of I kappa B-alpha in RAW264.7 macrophages. Toxicol Appl Phamacol, 2000, 169(1): 59-65.
  • 9Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia, 2001, 44(2): 129-146.
  • 10Speir E. Cytomegalovirus gene regulation by reactive oxygen species.Agents in Atherosclerosis. Ann NY Acad Sci, 2000, 899 (3): 363-374

共引文献30

同被引文献8

  • 1Gopalkrishnapillai B,Nadanathangam V,Karmakar N,et al.Evaluation of autofluorescent property of hemoglobin-advanced glycation end product as a long-term glycemic index of diabetes.Diabetes,2003,52:1041-1046.
  • 2Forbes J M,Yee LTL,Thallas V,et al.Advanced glycation end products interventions reduce diabetes-accelerated atherosclerosis.Diabetes,2004,53:1813-1823.
  • 3Tankova T,Cherninkova S,Koev D.Treatment for diabetic mononeuropathy with alpha-lipoic acid.Int J Clin Pract,2005,59:645-650.
  • 4Lee BW,Kwon SJ,Chae HY,et al.Dose-related cytoprotective effect of alpha-lipoic acid on hydrogen peroxide-induced oxidative stress to pancreatic beta cells.Free Radic Res,2009,43:68-77.
  • 5Lee SJ,Kang JG,Ryu OH,et al.Effect of alpha-lipoic acid on transforming growth factor betal-p38 mitogen-activated protein kinase-fibronectin pathway in diabetic nephropathy.Metabolism,2009,58:616-623.
  • 6Nakagami H,Kaneda Y,Ogihara Y,et al.Hepatocyte growth factor as potential cardiovascular therapy.Expert Rev Cardiovasc Ther,2005,3:513-519.
  • 7Ahmed N.Advanced glyeation end products-role in pathology of diabetic complications.Diabetes Res Clin Pract,2005,67:3-21.
  • 8宗传龙,周白云.葡多酚与硫辛酸对^(60)Coγ致小鼠肝损伤拮抗作用[J].中国公共卫生,2008,24(10):1229-1230. 被引量:4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部